In vivo expression of Streptococcus pyogenes immunogenic proteins during tibial foreign body infection

Infection and Immunity

Volumn 82, Issue 9, 2014, Pages 3891-3899

  Freiberg, Jeffrey A ^a   McIver, Kevin S ^b   Shirtliff, Mark E ^c,d  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANE PROTEIN; PEPTIDE NUCLEIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIUM COLONY; BIOFILM; BONE INFECTION; CONFOCAL MICROSCOPY; CONVALESCENCE; FLUORESCENCE IN SITU HYBRIDIZATION; FOREIGN BODY; GROUP A STREPTOCOCCAL INFECTION; GROWTH CURVE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; OSTEOMYELITIS; OSTEOSCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT MODEL; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; TANDEM MASS SPECTROMETRY; TIBIA; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANIMALS; BACTERIAL PROTEINS; BIOFILMS; FEMALE; FOREIGN BODIES; OSTEOMYELITIS; RABBITS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TIBIA;

EID: 84906071020     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01831-14     Document Type: Article

References (56)

1. Pichichero ME. 1998. Group A beta-hemolytic streptococcal infections. Pediatr. Rev. 19:291-302. http://dx.doi.org/10.1542/pir.19-9-291.
2. Steer AC, Lamagni T, Curtis N, Carapetis JR. 2012. Invasive group A streptococcal disease: epidemiology, pathogenesis and management. Drugs 72:1213-1227. http://dx.doi.org/10.2165/11634180-000000000-00000.
3. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5:685-694. http://dx.doi.org/10.1016/S1473-3099(05)70267-X.
4. Henningham A, Chiarot E, Gillen CM, Cole JN, Rohde M, Fulde M, Ramachandran V, Cork AJ, Hartas J, Magor G, Djordjevic SP, Cordwell SJ, Kobe B, Sriprakash KS, Nizet V, Chhatwal GS, Margarit IY, BatzloffMR, Walker MJ. 2012. Conserved anchorless surface proteins as group A streptococcal vaccine candidates. J. Mol. Med. 90:1197-1207. http://dx.doi.org/10.1007/s00109-012-0897-9.
5. Stevens DL. 1992. Invasive group A streptococcus infections. Clin. Infect. Dis. 14:2-11. http://dx.doi.org/10.1093/clinids/14.1.2.
6. Pichichero ME, Casey JR. 2007. Systematic review of factors contributing to penicillin treatment failure in Streptococcus pyogenes pharyngitis. Otolaryngol. Head Neck Surg. 137:851-857. http://dx.doi.org/10.1016/j.otohns.2007.07.033.
7. Baldassarri L, Creti R, Recchia S, Imperi M, Facinelli B, Giovanetti E, Pataracchia M, Alfarone G, Orefici G. 2006. Therapeutic failures of antibiotics used to treat macrolide-susceptible Streptococcus pyogenes infections may be due to biofilm formation. J. Clin. Microbiol. 44:2721-2727. http://dx.doi.org/10.1128/JCM.00512-06.
8. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-193. http://dx.doi.org/10.1128/CMR.15.2.167-193.2002.
9. Conley J, Olson ME, Cook LS, Ceri H, Phan V, Davies HD. 2003. Biofilm formation by group A streptococci: is there a relationship with treatment failure? J. Clin. Microbiol. 41:4043-4048. http://dx.doi.org/10.1128/JCM.41.9.4043-4048.2003.
10. Akiyama H, Morizane S, Yamasaki O, Oono T, Iwatsuki K. 2003. Assessment of Streptococcus pyogenes microcolony formation in infected skin by confocal laser scanning microscopy. J. Dermatol. Sci. 32:193-199. http://dx.doi.org/10.1016/S0923-1811(03)00096-3.
11. Roberts AL, Connolly KL, Kirse DJ, Evans AK, Poehling KA, Peters TR, Reid SD. 2012. Detection of group A Streptococcus in tonsils from pediatric patients reveals high rate of asymptomatic streptococcal carriage. BMC Pediatr. 12:3. http://dx.doi.org/10.1186/1471-2431-12-3.
12. Fiedler T, Riani C, Koczan D, Standar K, Kreikemeyer B, Podbielski A. 2013. Protective mechanisms of respiratory tract streptococci against Streptococcus pyogenes biofilm formation and epithelial cell infection. Appl. Environ. Microbiol. 79:1265-1276. http://dx.doi.org/10.1128/AEM.03350-12.
13. Marks LR, Reddinger RM, Hakansson AP. 2014. Biofilm formation enhances fomite survival of Streptococcus pneumoniae and Streptococcus pyogenes. Infect. Immun. 82:1141-1146. http://dx.doi.org/10.1128/IAI.01310-13.
14. Marks LR, Mashburn-Warren L, Federle MJ, Hakansson AP. 23 January 2014. Streptococcus pyogenes biofilm growth in vitro and in vivo and its role in colonization, virulence and genetic exchange. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jiu058.
15. Connolly KL, Roberts AL, Holder RC, Reid SD. 2011. Dispersal of group A streptococcal biofilms by the cysteine protease SpeB leads to increased disease severity in a murine model. PLoS One 6:e18984. http://dx.doi.org/10.1371/journal.pone.0018984.
16. Connolly KL, Braden AK, Holder RC, Reid SD. 2011. Srv mediated dispersal of streptococcal biofilms through SpeB is observed in CovRS+ strains. PLoS One 6:e28640. http://dx.doi.org/10.1371/journal.pone.0028640.
17. Roberts AL, Connolly KL, Doern CD, Holder RC, Reid SD. 2010. Loss of the group A Streptococcus regulator Srv decreases biofilm formation in vivo in an otitis media model of infection. Infect. Immun. 78:4800-4808. http://dx.doi.org/10.1128/IAI.00255-10.
18. Cho KH, Caparon MG. 2005. Patterns of virulence gene expression differ between biofilm and tissue communities of Streptococcus pyogenes. Mol. Microbiol. 57:1545-1556. http://dx.doi.org/10.1111/j.1365-2958.2005.04786.x.
19. Oliver-Kozup H, Martin KH, Schwegler-Berry D, Green BJ, Betts C, Shinde AV, Van De Water L, Lukomski S. 2013. The group A streptococcal collagen-like protein-1, Scl1, mediates biofilm formation by targeting the extra domain A-containing variant of cellular fibronectin expressed in wounded tissue. Mol. Microbiol. 87:672-689. http://dx.doi.org/10.1111/mmi.12125.
20. Auh JS, Binns HJ, Katz BZ. 2004. Retrospective assessment of subacute or chronic osteomyelitis in children and young adults. Clin. Pediatr. (Phila) 43:549-555. http://dx.doi.org/10.1177/000992280404300607.
21. Saavedra-Lozano J, Mejias A, Ahmad N, Peromingo E, Ardura MI, Guillen S, Syed A, Cavuoti D, Ramilo O. 2008. Changing trends in acute osteomyelitis in children: impact of methicillin-resistant Staphylococcus aureus infections. J. Pediatr. Orthop. 28:569-575. http://dx.doi.org/10.1097/BPO.0b013e31817bb816.
22. Ibia EO, Imoisili M, Pikis A. 2003. Group A beta-hemolytic streptococcal osteomyelitis in children. Pediatrics 112:e22-e26. http://dx.doi.org/10.1542/peds.112.1.e22.
23. Chatellier S, Ihendyane N, Kansal RG, Khambaty F, Basma H, Norrby-Teglund A, Low DE, McGeer A, Kotb M. 2000. Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect. Immun. 68:3523-3534. http://dx.doi.org/10.1128/IAI.68.6.3523-3534.2000.
24. Brady RA, Leid JG, Camper AK, Costerton JW, ShirtliffME. 2006. Identification of Staphylococcus aureus proteins recognized by the antibody-mediated immune response to a biofilm infection. Infect. Immun. 74:3415-3426. http://dx.doi.org/10.1128/IAI.00392-06.
25. Mader JT. 1985. Animal models of osteomyelitis. Am. J. Med. 78:213-217. http://dx.doi.org/10.1016/0002-9343(85)90387-0.
26. Mader JT, Morrison LT, Adams KR. 1987. Comparative evaluation of A-56619, A-56620, and nafcillin in the treatment of experimental Staphylococcus aureus osteomyelitis. Antimicrob. Agents Chemother. 31:259-263. http://dx.doi.org/10.1128/AAC.31.2.259.
27. Mader JT, Wilson KJ. 1983. Comparative evaluation of cefamandole and cephalothin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. J. Bone Joint Surg. Am. 65:507-513.
28. Mader JT, ShirtliffME. 1999. The rabbit model of bacterial osteomyelitis of the tibia, p 581-591. In Zak O, Sande MA (ed), Handbook of animal models of infection. Academic Press, London, United Kingdom.
29. Norden CW. 1970. Experimental osteomyelitis. I. A description of the model. J. Infect. Dis. 122:410-418. http://dx.doi.org/10.1093/infdis/122.5.410.
30. Cole JN, Djordjevic SP, Walker MJ. 2008. Isolation and solubilization of gram-positive bacterial cell wall-associated proteins. Methods Mol. Biol. 425:295-311. http://dx.doi.org/10.1007/978-1-60327-210-0_24.
31. Mitchell TJ. 2003. The pathogenesis of streptococcal infections: from tooth decay to meningitis. Nat. Rev. Microbiol. 1:219-230. http://dx.doi.org/10.1038/nrmicro771.
32. Cunningham MW. 2000. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13:470-511. http://dx.doi.org/10.1128/CMR.13.3.470-511.2000.
33. Dmitriev AV, Chaussee MS. 2010. The Streptococcus pyogenes proteome: maps, virulence factors and vaccine candidates. Future Microbiol. 5:1539-1551. http://dx.doi.org/10.2217/fmb.10.116.
34. Yu NY, Wagner JR, Laird MR, Melli G, Rey S, Lo R, Dao P, Sahinalp SC, Ester M, Foster LJ, Brinkman FS. 2010. PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics 26:1608-1615. http://dx.doi.org/10.1093/bioinformatics/btq249.
35. Cole JN, Ramirez RD, Currie BJ, Cordwell SJ, Djordjevic SP, Walker MJ. 2005. Surface analyses and immune reactivities of major cell wallassociated proteins of group A streptococcus. Infect. Immun. 73:3137-3146. http://dx.doi.org/10.1128/IAI.73.5.3137-3146.2005.
36. Davidson AL, Dassa E, Orelle C, Chen J. 2008. Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol. Mol. Biol. Rev. 72:317-364, table of contents. http://dx.doi.org/10.1128/MMBR.00031-07.
37. Higgins CF. 2001. ABC transporters: physiology, structure and mechanism-an overview. Res. Microbiol. 152:205-210. http://dx.doi.org/10.1016/S0923-2508(01)01193-7.
38. Beloin C, Ghigo JM. 2005. Finding gene-expression patterns in bacterial biofilms. Trends Microbiol. 13:16-19. http://dx.doi.org/10.1016/j.tim.2004.11.008.
39. Roberts ME, Stewart PS. 2004. Modeling antibiotic tolerance in biofilms by accounting for nutrient limitation. Antimicrob. Agents Chemother. 48:48-52. http://dx.doi.org/10.1128/AAC.48.1.48-52.2004.
40. Rani SA, Pitts B, Beyenal H, Veluchamy RA, Lewandowski Z, Davison WM, Buckingham-Meyer K, Stewart PS. 2007. Spatial patterns of DNA replication, protein synthesis, and oxygen concentration within bacterial biofilms reveal diverse physiological states. J. Bacteriol. 189:4223-4233. http://dx.doi.org/10.1128/JB.00107-07.
41. Anderl JN, Zahller J, Roe F, Stewart PS. 2003. Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother. 47: 1251-1256. http://dx.doi.org/10.1128/AAC.47.4.1251-1256.2003.
42. Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sorensen SR, Moser C, Kuhl M, Jensen PO, Hoiby N. 2013. The in vivo biofilm. Trends Microbiol. 21:466-474. http://dx.doi.org/10.1016/j.tim.2013.06.002.
43. Costerton JW, Lewandowski Z, DeBeer D, Caldwell D, Korber D, James G. 1994. Biofilms, the customized microniche. J. Bacteriol. 176:2137-2142.
44. Lei B, Liu M, Chesney GL, Musser JM. 2004. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins. J. Infect. Dis. 189:79-89. http://dx.doi.org/10.1086/380491.
45. Janulczyk R, Ricci S, Bjorck L. 2003. MtsABC is important for manganese and iron transport, oxidative stress resistance, and virulence of Streptococcus pyogenes. Infect. Immun. 71:2656-2664. http://dx.doi.org/10.1128/IAI.71.5.2656-2664.2003.
46. Talkington DF, Brown BG, Tharpe JA, Koenig A, Russell H. 1996. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb. Pathog. 21:17-22. http://dx.doi.org/10.1006/mpat.1996.0038.
47. Wang S, Li Y, Shi H, Scarpellini G, Torres-Escobar A, Roland KL, Curtiss R, III. 2010. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect. Immun. 78:3258-3271. http://dx.doi.org/10.1128/IAI.00176-10.
48. Brady RA, O'May GA, Leid JG, Prior ML, Costerton JW, ShirtliffME. 2011. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect. Immun. 79:1797-1803. http://dx.doi.org/10.1128/IAI.00451-10.
49. Metzgar D, Zampolli A. 2011. The M protein of group A Streptococcus is a key virulence factor and a clinically relevant strain identification marker. Virulence 2:402-412. http://dx.doi.org/10.4161/viru.2.5.16342.
50. Chiang-Ni C, Wu JJ. 2008. Effects of streptococcal pyrogenic exotoxin B on pathogenesis of Streptococcus pyogenes. J. Formos. Med. Assoc. 107: 677-685. http://dx.doi.org/10.1016/S0929-6646(08)60112-6.
51. Doern CD, Roberts AL, Hong W, Nelson J, Lukomski S, Swords WE, Reid SD. 2009. Biofilm formation by group A Streptococcus: a role for the streptococcal regulator of virulence (Srv) and streptococcal cysteine protease (SpeB). Microbiology 155:46-52. http://dx.doi.org/10.1099/mic.0.021048-0.
52. Nobbs AH, Lamont RJ, Jenkinson HF. 2009. Streptococcus adherence and colonization. Microbiol. Mol. Biol. Rev. 73:407-450, table of contents. http://dx.doi.org/10.1128/MMBR.00014-09.
53. Cunningham MW. 2012. Streptococcus and rheumatic fever. Curr. Opin. Rheumatol. 24:408-416. http://dx.doi.org/10.1097/BOR.0b013e32835461d3.
54. Dale JB, Penfound TA, Tamboura B, Sow SO, Nataro JP, Tapia M, KotloffKL. 2013. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine 31:1576-1581. http://dx.doi.org/10.1016/j.vaccine.2013.01.019.
55. Guilherme L, Ferreira FM, Kohler KF, Postol E, Kalil J. 2013. A vaccine against Streptococcus pyogenes: the potential to prevent rheumatic fever and rheumatic heart disease. Am. J. Cardiovasc. Drugs 13:1-4. http://dx.doi.org/10.1007/s40256-013-0005-8.
56. Henningham A, Ericsson DJ, Langer K, Casey LW, Jovcevski B, Chhatwal GS, Aquilina JA, BatzloffMR, Kobe B, Walker MJ. 2013. Structure-informed design of an enzymatically inactive vaccine component for group A Streptococcus. mBio 4:e00509-13. http://dx.doi.org/10.1128/mBio.00509-13.